v3.26.1
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Collaboration and license revenue $ 0 $ 400
Grant revenue 78 700
Total revenues 78 1,100
Operating expenses:    
Research and development 19,463 14,674
General and administrative 7,114 8,315
Net loss (39,182) (17,710)
Operating Segment    
Revenue:    
Collaboration and license revenue 0 400
Grant revenue 78 700
Total revenues 78 1,100
Operating expenses:    
General and administrative 7,114 8,315
Other expense (income), net 12,683 (4,179)
Net loss (39,182) (17,710)
Operating Segment | Descartes-08 for MG    
Operating expenses:    
Research and development 12,135 7,036
Operating Segment | Descartes-08 for dermatomyositis    
Operating expenses:    
Research and development 227 0
Operating Segment | Early stage programs    
Operating expenses:    
Research and development 355 990
Operating Segment | Research and development employee expenses    
Operating expenses:    
Research and development 3,828 3,702
Operating Segment | Research and development stock-based compensation expense    
Operating expenses:    
Research and development 949 1,275
Operating Segment | Research and development facilities and other expenses    
Operating expenses:    
Research and development $ 1,969 $ 1,671